Johnson & Johnson Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Joaquin Duato
Chief executive officer
US$28.4m
Total compensation
| CEO salary percentage | 5.6% |
| CEO tenure | 3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 5.1yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 29 2024 | n/a | n/a | US$15b |
| Jun 30 2024 | n/a | n/a | US$16b |
| Mar 31 2024 | n/a | n/a | US$17b |
| Dec 31 2023 | US$28m | US$2m | US$13b |
| Oct 01 2023 | n/a | n/a | US$12b |
| Jul 02 2023 | n/a | n/a | US$12b |
| Apr 02 2023 | n/a | n/a | US$11b |
| Jan 01 2023 | US$13m | US$1m | US$16b |
| Oct 02 2022 | n/a | n/a | US$18b |
| Jul 03 2022 | n/a | n/a | US$17b |
| Apr 03 2022 | n/a | n/a | US$20b |
| Jan 02 2022 | US$14m | US$1m | US$18b |
| Oct 03 2021 | n/a | n/a | US$18b |
| Jul 04 2021 | n/a | n/a | US$18b |
| Apr 04 2021 | n/a | n/a | US$15b |
| Jan 03 2021 | n/a | n/a | US$15b |
| Sep 27 2020 | n/a | n/a | US$17b |
| Jun 28 2020 | n/a | n/a | US$15b |
| Mar 29 2020 | n/a | n/a | US$17b |
| Dec 29 2019 | US$13m | US$970k | US$15b |
| Sep 29 2019 | n/a | n/a | US$14b |
| Jun 30 2019 | n/a | n/a | US$16b |
| Mar 31 2019 | n/a | n/a | US$15b |
| Dec 30 2018 | US$9m | US$934k | US$15b |
Compensation vs Market: Joaquin's total compensation ($USD28.40M) is above average for companies of similar size in the UK market ($USD5.75M).
Compensation vs Earnings: Joaquin's compensation has increased by more than 20% in the past year.
CEO
Joaquin Duato (61 yo)
3yrs
Tenure
US$28,397,240
Compensation
Mr. Joaquin Duato serves as Chief Executive Officer & Director of Johnson & Johnson since January 3, 2022 and serves as its Chairman since January 02, 2023. He served as Worldwide Chairman of Pharmaceutica...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 3yrs | US$28.40m | 0.015% $ 52.7m | |
| Executive VP & CFO | 6.5yrs | US$13.91m | 0.0029% $ 10.3m | |
| Executive VP & Worldwide Chairman of Innovative Medicine | 13yrs | US$11.00m | 0.0064% $ 22.4m | |
| Executive Vice President of Innovative Medicine | 1.8yrs | US$20.65m | 0.00061% $ 2.1m | |
| Controller & Chief Accounting Officer | 5.1yrs | no data | 0.00082% $ 2.9m | |
| Executive VP & Chief Information Officer | 5.2yrs | no data | 0.00061% $ 2.1m | |
| Vice President of Investor Relations | 3.2yrs | no data | no data | |
| Chief Compliance Officer | no data | no data | no data | |
| Executive VP & Chief Legal Officer | 2.3yrs | no data | 0.00035% $ 1.2m | |
| Group Chairman of MD&D Business - EMEA | no data | no data | no data | |
| Executive VP and Chief Technical Operations & Risk Officer | 6.5yrs | no data | 0.0034% $ 11.9m | |
| Executive Vice President of Global Corporate Affairs | 7yrs | no data | 0.00082% $ 2.9m |
5.1yrs
Average Tenure
58yo
Average Age
Experienced Management: 0R34's management team is seasoned and experienced (5.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 3yrs | US$28.40m | 0.015% $ 52.7m | |
| Independent Director | 16yrs | US$410.00k | 0.00034% $ 1.2m | |
| Independent Director | 5.1yrs | US$320.00k | 0.00021% $ 731.2k | |
| Lead Independent Director | 5.8yrs | US$360.00k | 0.00012% $ 417.8k | |
| Independent Director | 1.9yrs | US$352.97k | 0.000010% $ 34.8k | |
| Independent Director | 11.3yrs | US$320.00k | 0% $ 0 | |
| Independent Director | 9.6yrs | US$355.00k | 0% $ 0 | |
| Independent Director | 2.9yrs | US$340.00k | 0.000040% $ 139.3k | |
| Independent Director | 6.8yrs | US$320.00k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$89.15k | no data | |
| Independent Director | 5.1yrs | US$340.00k | 0.000040% $ 139.3k | |
| Independent Director | 4.1yrs | US$340.00k | 0% $ 0 |
5.1yrs
Average Tenure
62.5yo
Average Age
Experienced Board: 0R34's board of directors are considered experienced (5.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 12:08 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/29 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Johnson & Johnson is covered by 59 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Matt Miksic | Barclays |